دورية أكاديمية
أعرض في EDS

Mesenchymal Stem Cell-Derived Exosomes as Drug Carriers for Delivering miRNA-29b to Ameliorate Inflammation in Corneal Injury Via Activating Autophagy.

التفاصيل البيبلوغرافية
العنوان: Mesenchymal Stem Cell-Derived Exosomes as Drug Carriers for Delivering miRNA-29b to Ameliorate Inflammation in Corneal Injury Via Activating Autophagy.
المؤلفون: Liu J; School of Medicine, Nankai University, Tianjin, China; Nankai University Affiliated Eye Hospital, Tianjin, China.; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Vision Science, Tianjin Eye Institute, Tianjin, China., Gao J; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Vision Science, Tianjin Eye Institute, Tianjin, China., Lu P; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Vision Science, Tianjin Eye Institute, Tianjin, China., Wang Y; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Vision Science, Tianjin Eye Institute, Tianjin, China., Xing S; Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China., Yan Y; Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China., Han R; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Vision Science, Tianjin Eye Institute, Tianjin, China., Hao P; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Vision Science, Tianjin Eye Institute, Tianjin, China., Li X; School of Medicine, Nankai University, Tianjin, China; Nankai University Affiliated Eye Hospital, Tianjin, China.; Tianjin Eye Hospital, Tianjin Key Lab of Ophthalmology and Vision Science, Tianjin Eye Institute, Tianjin, China.; Clinical College of Ophthalmology, Tianjin Medical University, Tianjin, China.
المصدر: Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2024 Jun 03; Vol. 65 (6), pp. 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Association For Research In Vision And Ophthalmology (Arvo) Country of Publication: United States NLM ID: 7703701 Publication Model: Print Cited Medium: Internet ISSN: 1552-5783 (Electronic) Linking ISSN: 01460404 NLM ISO Abbreviation: Invest Ophthalmol Vis Sci Subsets: MEDLINE
أسماء مطبوعة: Publication: Brookline Ma : Association For Research In Vision And Ophthalmology (Arvo)
Original Publication: St. Louis, Mosby.
مواضيع طبية MeSH: Autophagy* , MicroRNAs*/genetics , Exosomes*/metabolism , Exosomes*/transplantation , Mesenchymal Stem Cells*/metabolism , Mice, Inbred C57BL* , Corneal Injuries*/metabolism , Corneal Injuries*/genetics , Corneal Injuries*/therapy , Disease Models, Animal*, Animals ; Mice ; Drug Carriers ; Inflammation/metabolism ; Male ; Cells, Cultured ; Humans ; Blotting, Western
مستخلص: Purpose: Corneal injury (CI) resulting in corneal opacity remains a clinical challenge. Exosomes (Exos) derived from bone marrow mesenchymal stem cells (BMSCs) have been proven effective in repairing various tissue injuries and are also considered excellent drug carriers due to their biological properties. Recently, microRNA-29b (miR-29b) was found to play an important role in the autophagy regulation which correlates with cell inflammation and fibrosis. However, the effects of miR-29b and autophagy on CI remain unclear. To find better treatments for CI, we used Exos to carry miR-29b and investigated its effects in the treatment of CI.
Methods: BMSCs were transfected with miR-29b-3p agomir/antagomir and negative controls (NCs) to obtain Exos-29b-ago, Exos-29b-anta, and Exos-NC. C57BL/6J mice that underwent CI surgeries were treated with Exos-29b-ago, Exos-29b-anta, Exos-NC, or PBS. The autophagy, inflammation, and fibrosis of the cornea were estimated by slit-lamp, hematoxylin and eosin (H&E) staining, immunofluorescence, RT‒qPCR, and Western blot. The effects of miR-29b-3p on autophagy and inflammation in immortalized human corneal epithelial cells (iHCECs) were also investigated.
Results: Compared to PBS, Exos-29b-ago, Exos-29b-anta, and Exos-NC all could ameliorate corneal inflammation and fibrosis. However, Exos-29b-ago, which accumulated a large amount of miR-29b-3p, exerted excellent potency via autophagy activation by inhibiting the PI3K/AKT/mTOR pathway and further inhibited corneal inflammation via the mTOR/NF-κB/IL-1β pathway. After Exos-29b-ago treatment, the expressions of collagen type III, α-smooth muscle actin, fibronectin, and vimentin were significantly decreased than in other groups. In addition, overexpression of miR-29b-3p prevented iHCECs from autophagy impairment and inflammatory injury.
Conclusions: Exos from BMSCs carrying miR-29b-3p can significantly improve the therapeutic effect on CI via activating autophagy and further inhibiting corneal inflammation and fibrosis.
References: Photodermatol Photoimmunol Photomed. 2023 May;39(3):235-245. (PMID: 35950642)
J Cell Sci. 2022 Jul 15;135(14):. (PMID: 35735031)
Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):41. (PMID: 35089329)
Stem Cells Transl Med. 2017 Apr;6(4):1273-1285. (PMID: 28198592)
Cell Death Discov. 2021 Aug 11;7(1):212. (PMID: 34381025)
J Control Release. 2015 Dec 10;219:396-405. (PMID: 26241750)
J Neuroinflammation. 2022 Feb 7;19(1):35. (PMID: 35130907)
Exp Eye Res. 2022 Feb;215:108909. (PMID: 34968473)
Brain Res Bull. 2010 Feb 15;81(2-3):229-35. (PMID: 19733636)
Oncol Lett. 2022 Jul 01;24(2):289. (PMID: 35928803)
Int J Mol Med. 2021 Jun;47(6):. (PMID: 33907817)
Mol Ther. 2014 May;22(5):974-85. (PMID: 24569834)
Autophagy. 2020 May;16(5):782-796. (PMID: 31286822)
Cell Death Differ. 2021 Mar;28(3):1041-1061. (PMID: 33082517)
Mol Cell. 2008 Apr 25;30(2):214-26. (PMID: 18439900)
Immunity. 2017 Jan 17;46(1):38-50. (PMID: 27986454)
Chin Med J (Engl). 2019 Mar 20;132(6):664-670. (PMID: 30855347)
Cell Signal. 2020 Oct;74:109716. (PMID: 32707074)
Cell Biosci. 2021 Mar 26;11(1):61. (PMID: 33771228)
Theranostics. 2021 Jan 1;11(7):3183-3195. (PMID: 33537081)
Cell. 2011 Nov 11;147(4):728-41. (PMID: 22078875)
Biomaterials. 2021 Aug;275:120902. (PMID: 34087588)
EBioMedicine. 2018 Sep;35:345-360. (PMID: 30170968)
Kaohsiung J Med Sci. 2021 Dec;37(12):1069-1076. (PMID: 34369661)
Biochem Biophys Res Commun. 2011 Aug 19;412(1):74-9. (PMID: 21798245)
Ocul Surf. 2019 Apr;17(2):186-197. (PMID: 30690084)
Autophagy. 2020 Jan;16(1):38-51. (PMID: 31286804)
J Bioenerg Biomembr. 2022 Apr;54(2):81-91. (PMID: 35322290)
Mol Cells. 2018 Jan 31;41(1):11-17. (PMID: 29370692)
Invest Ophthalmol Vis Sci. 2012 Nov 01;53(12):7476-83. (PMID: 23049092)
J Immunol Res. 2022 Oct 14;2022:4769385. (PMID: 36277474)
Sci Rep. 2017 May 10;7(1):1663. (PMID: 28490734)
Oral Oncol. 2014 Nov;50(11):1062-71. (PMID: 25127200)
Nature. 2017 Dec 21;552(7685):368-373. (PMID: 29236692)
Cell Mol Neurobiol. 2016 Apr;36(3):417-27. (PMID: 27017608)
Biomed Pharmacother. 2020 May;125:109895. (PMID: 32000066)
Int J Mol Sci. 2021 Jan 15;22(2):. (PMID: 33467546)
Biochem Pharmacol. 2023 May;211:115534. (PMID: 37019186)
Autophagy. 2007 Nov-Dec;3(6):542-5. (PMID: 17611390)
Theranostics. 2020 Jul 23;10(20):9280-9302. (PMID: 32802192)
Cells. 2020 Feb 28;9(3):. (PMID: 32121073)
Bioconjug Chem. 2019 Apr 17;30(4):994-1005. (PMID: 30855944)
Int J Biol Sci. 2016 Oct 25;12(11):1332-1340. (PMID: 27877085)
Blood. 2015 Sep 3;126(10):1224-33. (PMID: 26209658)
J Biol Chem. 2008 Aug 15;283(33):22847-57. (PMID: 18524774)
Signal Transduct Target Ther. 2022 Jun 20;7(1):196. (PMID: 35725836)
Cornea. 2016 Nov;35(11):1466-1470. (PMID: 27490049)
Autophagy. 2019 May;15(5):753-770. (PMID: 30523761)
Ophthalmic Res. 1997;29(3):145-53. (PMID: 9211467)
J Mol Med (Berl). 2016 May;94(5):583-96. (PMID: 26687115)
FEBS Lett. 2010 Apr 2;584(7):1287-95. (PMID: 20083114)
J Exp Med. 1996 Mar 1;183(3):1161-72. (PMID: 8642258)
Invest Ophthalmol Vis Sci. 2012 Mar 26;53(3):1670-8. (PMID: 22297492)
Int Immunopharmacol. 2020 Jun;83:106468. (PMID: 32279044)
Cell. 2004 Jan 23;116(2):281-97. (PMID: 14744438)
J Am Soc Nephrol. 2012 Feb;23(2):252-65. (PMID: 22095944)
J Cell Biochem. 2014 Nov;115(11):1974-84. (PMID: 24913975)
Int J Pharm. 2018 Oct 25;550(1-2):100-113. (PMID: 30138707)
Blood Cells Mol Dis. 2005 Sep-Oct;35(2):94-110. (PMID: 15975838)
Nat Commun. 2017 May 25;8:15201. (PMID: 28541289)
J Hepatol. 2020 Nov;73(5):1144-1154. (PMID: 32389810)
JACC Basic Transl Sci. 2019 Feb 25;4(1):72-82. (PMID: 30847421)
Autophagy. 2021 Feb;17(2):385-401. (PMID: 32048886)
المشرفين على المادة: 0 (MicroRNAs)
0 (Drug Carriers)
0 (MIRN29 microRNA, mouse)
0 (MIRN29a microRNA, human)
تواريخ الأحداث: Date Created: 20240610 Date Completed: 20240610 Latest Revision: 20240613
رمز التحديث: 20240613
مُعرف محوري في PubMed: PMC11166224
DOI: 10.1167/iovs.65.6.16
PMID: 38856990
قاعدة البيانات: MEDLINE
الوصف
تدمد:1552-5783
DOI:10.1167/iovs.65.6.16